Atossa Therapeutics appoints CORE IR for investor relations

Atossa Therapeutics (ATOS) announces it has appointed CORE IR, a strategic investor relations, public relations, and corporate advisory firm, to support the Company’s ongoing investor relations and communications initiatives. Dr. Steven Quay, Chairman and CEO of Atossa, commented, “Our collaboration with CORE IR represents our continued commitment to drive value for our stakeholders and with the investment community. We are executing to plan and excited to communicate our progress with increasing market visibility. We believe CORE IR’s stewardship will help us better articulate our value proposition to existing and prospective shareholders.”